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REVIEW CURRENTOPINION Acceptance of standardized ultrasound
classification, use of albendazole, and long-term
follow-up in clinical management of cystic
echinococcosis: a systematic reviewCopyright © Lippincott W
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Enrico Brunettia,b,cPurpose of review
Cystic echinococcosis is a chronic, complex, and neglected disease. The need for a simple classification of
cyst morphology that would provide an accepted framework for scientific and clinical work on cystic
echinococcosis has been addressed by two documents issued by the WHO Informal Working Group on
Echinococcosis in 2003 (cyst classification) and in 2010 (Expert consensus for the diagnosis and treatment
of echinococcosis).
Recent findings
Here we evaluate the use of the WHO Informal Working Group on Echinococcosis classification of hepatic
cystic echinococcosis, the acceptance by clinicians of recommendations regarding the use of albendazole,
and the implementation of the long-term follow-up of patients with hepatic cystic echinococcosis in the
scientific literature since the WHO Informal Working Group on Echinococcosis recommendations were
issued.
Summary
Of the publications included in our review, 71.2% did not indicate any classification, whereas 14% used
the WHO Informal Working Group on Echinococcosis classification. Seventy-four percent reported the
administration of peri-interventional albendazole, although less than half reported its modality, and 51%
the length of patient follow-up. A joint effort is needed from the scientific community to encourage the
acceptance and implementation of these three key issues in the clinical management of cystic
echinococcosis.
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Cystic echinococcosis is a chronic, complex, and
neglected zoonotic disease, endemic in livestock
breedingareas throughout theworld [1,2]. It is caused
by the larval form (metacestode – hydatid cyst) of the
dog tapeworm Echinococcus granulosus, which devel-
ops in organs and tissues of the intermediate hosts.
These hosts include sheep and other livestock; how-
ever, humans can be accidental intermediate hosts.
Although all organs and tissues can be affected, the
cysts develop most commonly in the liver, in which
they evolve over years, often in the absence of symp-
toms. Although the exact sequence of structural and
metabolic changes during their natural history is stillilliams & Wilkins. Unau
Health | Lippincott Williams & Wilkunclear, longitudinal studies using ultrasound in
untreated people have shown that echinococcal
cysts may evolve spontaneously from unilocularthorized reproduction of this article is prohibited.
ins www.co-infectiousdiseases.com
CKEY POINTS
 Cystic echinococcosis is a chronic, complex and
neglected disease with a worldwide distribution.
 Cystic echinococcosis cysts show morphological
heterogeneity, which reflects different biological
activities and, of great importance, correlate with
different response rates to nonsurgical treatments,
implying the need for a stage-specific clinical
approach.
 Two documents issued by the WHO-IWGE in 2003
(cyst classification) and in 2010 (Expert Consensus for
the Diagnosis and Treatment of Echinococcosis)
provided a framework for scientific and clinical work
on cystic echinococcosis.
 The WHO-IWGE classification of hepatic cystic
echinococcosis, the indications regarding use of
albendazole, and the need for a long-term follow-up of
patients are three key points in clinical management of
cystic echinococcosis indicated by these documents.
 This literature survey shows that these three crucial
updates are still underreported, and likely ignored,
indicating that a joint effort is needed, from all the
scientific community, to encourage their reception
and implementation.
Tropical and travel-associated diseasesfluid-filled cysts to formswith semi-solid content and
calcified wall, passing through other morphologi-
cally different stages, including detached endocyst
and presence of daughter vesicles [3]. This morpho-
logical heterogeneity reflects different states of the
cysts’ biological activity [4] and, of great importance,
correlateswithdifferent response rates tononsurgical
treatments [5–7]. Furthermore, the rate of positive
serology differs between patients with hepatic
cystic echinococcosis in different stages [8]. As a
consequence, there has been a need for a simple
classification of cysts morphology that reflects bio-
logical changes, to provide an internationally
accepted framework for clinical and scientific work
on cystic echinococcosis, and for stage-specific
clinical management guidelines. This has been
addressed by the WHO Informal Working Group
on Echinococcosis (WHO-IWGE) in 2003 when it
issued the ‘International classification of ultrasound
images in cystic echinococcosis for application in
clinical and field epidemiological settings’ [9] and
in 2010 with the publication of the ‘Expert consen-
sus for the diagnosis and treatment of cystic and
alveolar echinococcosis in humans’ [10
&&
]. However,
substantial heterogeneity in reporting cystic echino-
coccosis morphology and patients clinical manage-
ment still exists. Recently, Chiodini and Nabarro
(Symposium ‘Innovation for the management ofopyright © Lippincott Williams & Wilkins. Unautho
426 www.co-infectiousdiseases.comEchinococcosis’, 27–29 March 2014, Besanc¸on,
France) conducted anonline surveyon the treatment
options that clinicians around the world would
choose in five clinical cases of cystic echinococcosis.
They found not only extremely heterogeneous
managements of the same cases but also a worrying
number of unsafe or not recommended practices.
Here we evaluate the use of the WHO-IWGE
classification of hepatic cystic echinococcosis, the
reception of indications regarding use of albenda-
zole, which is still the only drug available for cystic
echinococcosis, and the need for a long-term follow-
up of patients with hepatic cystic echinococcosis,
three key points in clinical management of cystic
echinococcosis indicated by these documents, in
the scientific literature on hepatic cystic echinococ-
cosis since their publication.LITERATURE SEARCH
Weperformed a PubMed (MEDLINE) literature search
using the keywords ‘Echinococcus’, ‘Echinococcus
granulosus’, ‘cystic echinococcosis’, ‘cystic hyda-
tidosis’, ‘hydatid disease’, ‘liver’, ‘hepatic’. We
restricted the search to human studies and to the
period 1 December 2010–30 April 2014 for the
investigation on the use of albendazole and fol-
low-up reporting, and to the period 1 January
2004–30 April 2014 for the investigation on the
use of cystic echinococcosis classification. These
dates were chosen accounting for about 1 year
between the issue of the two reference WHO-IWGE
documents and the implementation of their con-
tent in field and clinical practice, and therefore in
publications. Original papers (case reports, case
series, cohort studies, case–control studies, cross-
sectional studies, clinical trials, diagnostic studies)
reporting data from individual patients with hepatic
cystic echinococcosis and including imaging were
considered eligible. Publications on postinterven-
tional complications not providing data on the
preinterventional hepatic cystic echinococcosis
lesion were excluded. Studies investigating the per-
formances of diagnostic tools (serology or imaging)
or diagnostic case reports were included only in the
investigation on the use of cystic echinococcosis
classification. Similarly, when data reported in
papers published after December 2010 referred
explicitly to patients visited before this date, only
data regarding the use of the cystic echinococcosis
classification were extracted. Data on albendazole
use and follow-up were extracted from eligible
papers published after December 2010. Publications
in English, French, Spanish, Italian, or German, and
publications in other languages in which the
abstract in English did report the requiredrized reproduction of this article is prohibited.
Volume 27  Number 5  October 2014
Clinical management of cystic echinococcosis Tamarozzi et al.information, were considered eligible. The complete
list of publications included in the analysis is
available as supplementary material. These were
33 case–control or cohort studies, 93 case series
(including  four patients), 239 case reports, two
clinical trials, nine cross-sectional studies, and 44
diagnostic studies. The flow diagram of electronic
search and selection of publications is shown in
Fig. 1.CLASSIFICATION OF HEPATIC CYSTIC
ECHINOCOCCOSIS CYSTS
The diagnosis and clinical management of cystic
echinococcosis have evolved over decades in the
absence of a systematic approach [11,12]. The first
widely used ultrasound classification of hepatic
cystic echinococcosis cysts has been proposed by
Gharbi et al. [13] in 1981 and has been used in the
following years as the basis for a number of other
classifications [14–18]. The heterogeneity of these
classifications resulted in the impossibility to com-
pare the observations and treatment protocols made
by investigators in various clinical andCopyright © Lippincott Williams & Wilkins. Unau
1563 citations retrieved in MEDLINE
using electronic search
01/01/2004 – 30/04/2014
286 Extra-hepatic localization of CE
235 Other Echinococcus species
217 Type of publication other than original
papers reporting data from individual
patients including imaging
137 Publications in other languages and
abstract either not available or not providing
the needed information
128 Nonparasitic cysts
71 Publication of data collected before 2004
55 Full paper not available and abstract
either not available or not providing the
needed information
12 Animal study
2 Duplicate publications
420 publications meeting the inclusion criteria
1143 excluded publications:
FIGURE 1. Flow diagram of electronic search and selection
of publications for the evaluation of the use of WHO
Informal Working Group on Echinococcosis classification.
0951-7375  2014 Wolters Kluwer Health | Lippincott Williams & Wilkepidemiological settings, which were not reported
in a uniform manner. To overcome this problem, in
2003, the WHO-IWGE issued a standardized classi-
fication of hepatic cystic echinococcosis cysts ‘to
facilitate both the uniform reporting of results from
field epidemiological studies as well as in clinical
studies conducted in different parts of the world’,
which could be easy to use in different settings and
could reflect physiopathological mechanisms of
cystic echinococcosis [9] (Fig. 2). The main differ-
ences between WHO-IWGE and Gharbi classifi-
cations are the introduction of the category
‘cystic lesion’ to accommodate uniloculated cysts
without pathognomonic signs of cystic echinococ-
cosis for which further diagnostic procedures are
necessary and the reversing of the order between
Gharbi type II and type III cysts into cystic echino-
coccosis type 3 and cystic echinococcosis type 2
stages, respectively. The WHO-IWGE classification
also introduced the differentiation of multilocu-
lated cysts into two distinct categories to accommo-
date univocally those cysts with daughter vesicles
immersed in a semi-solid matrix. This overcame the
ambiguity in the classification of these cysts, which
could be assigned either to type III or type IV when
using the Gharbi classification. Moreover, the
WHO-IWGE classification introduced the grouping
of cystic echinococcosis cysts into three clinical
categories: active, transitional, and inactive, reflect-
ing the current knowledge of the natural history of
cystic echinococcosis (CE). Accordingly, unilocular
cysts (CE1) and multiloculated cysts with daughter
vesicles without solid matrix (CE2) were classified as
active cysts; cysts with detached endocysts and
multiloculated cysts with daughter vesicles in a solid
matrix were classified in the transitional group
(CE3); and cysts with solid content with (CE5) or
without (CE4) calcifications were classified as inac-
tive cysts. CE3 cysts have been further differentiated
into CE3a (with detached endocyst) and CE3b (pre-
dominantly solid with daughter vesicles) [11]. This
important distinction not only reflects the differ-
ence in cystmorphology but alsomirrors substantial
differences in their biological activity (CE3a cysts
are inactive in about half of the cases, whereas CE3b
are metabolically active), and in their response to
nonsurgical treatment (CE3a cysts respond well
to nonsurgical treatments, whereas CE3b cysts
most frequently relapse after these interventions)
[4,7,11].
Our literature search of scientific papers pub-
lished after January 2004 retrieved 1563 results. Of
these, 420 were eligible according to inclusion
criteria (Fig. 1). Overall, 299 eligible publications
(71.2%) did not include any classification of the
hepatic cystic echinococcosis cysts described. Ofthorized reproduction of this article is prohibited.
ins www.co-infectiousdiseases.com 427
CWHO-IWGE
[2003]
CE1 CE2
CE3a CE3b
CE4 CE5
Active
Transitional
Inactive
Gharbi
[1981]
Perdomo
[1995]
P 1a, P 1b, P 1c
P 3
P 4, P 4a
P 5, P 6
Caremani
[1997]
GI
GIII
GII
GIV
GV CVa, CVb
CVI
CVIla, CVllb
C la      C Ib
ClIa, ClIb
ClIla, C IIlb
CIV
FIGURE 2. Ultrasound classification systems of cystic echinococcosis cysts.
Tropical and travel-associated diseasesthe remaining 121 publications that included a cyst
classification, 59 (48.8%) used the WHO-IWGE
classification, 58 (47.9%) the Gharbi classification,
and four (3.3%) other classifications (cystic echino-
coccosis classification of the Tunisian surgical
association, n¼1; Caremani classification, n¼1;
Kilani classification of hydatid disease of the liver
with thoracic involvement, n¼1, parasite, node,
metastasis (PNM) staging, n¼1). Of note, PNM stag-
ing is used in case of alveolar echinococcosis; how-
ever, the manuscript referring to it, a case series
paper from Greece, constantly referred to ‘hydatid
cysts of the liver’, therefore assuming that E. gran-
ulosus was the etiological agent of the cysts.
When we investigated the use of cystic echino-
coccosis classifications by publication type, we
found that the majority (85.4%) of case reports
did not indicate any cyst classification in the case
description, although absence of classification
occurred in 66.7% of cross-sectional studies,
58.1% of case series, 54.5% of diagnostic studies,
and 51.5% of case control/cohort studies. When
publications reported a cyst classification, this was
prevalently the Gharbi compared with the WHO-
IWGE in case series (23.7 vs. 18.3%), case reports (7.5
vs. 6.3%), and case control/cohort studies (27.3 vs.
21.2%), whereas the reverse was found for diagnos-
tic studies (6.8 vs. 38.6%) and cross-sectional studies
(11.1 vs. 22.2%). Either WHO-IWGE or Gharbi
classification were used in the two clinical trialsopyright © Lippincott Williams & Wilkins. Unautho
428 www.co-infectiousdiseases.comincluded in the analysis. Results are detailed in
Table 1.
When we considered the results by year of pub-
lication, we found no fundamental changes over
time in the proportion of publications reporting
or not reporting a cystic echinococcosis classifi-
cation, with less than 40% of publications actually
including any cystic echinococcosis classification.
Of these, the Gharbi andWHO-IWGE classifications
were used in comparable proportions (Fig. 3).ALBENDAZOLE USE AND REPORT OF
FOLLOW-UP
The clinical management of cystic echinococcosis
performed by different centres is extremely hetero-
geneous. In the past, surgery has been the only
treatment modality for cystic echinococcosis, but
with the introduction of benzimidazoles from the
mid-1970s [19,20] and the development of percuta-
neous treatment in the mid-1980s [21], new options
became available and were widely used in the fol-
lowing decades. Furthermore, the so-called ‘watch-
and-wait’ approach to uncomplicated inactive cysts
has also been introduced on the basis of the obser-
vation that a good proportion of cysts become spon-
taneously inactive without any treatment and such
cysts are likely to remain stable over time [11]. No
‘one-size-fits-all’ treatment for cystic echinococco-
sis exists because of the proteiform presentation andrized reproduction of this article is prohibited.
Volume 27  Number 5  October 2014
Table 1. Results of the literature search
Reporting of cystic echinococcosis classification between January 2004 and April 2014 per type of publication
Case report Case series Cohort case-control Cross-sectional Clinical trials Diagnostic studies
No classification 205 (85.4%) 54 (58.1%) 17 (51.5%) 6 (66.7%) – 24 (54.5%)
WHO-IWGE 15 (6.3%) 17 (18.3%) 7 (21.2%) 2 (22.2%) 1 (50%) 17 (38.6%)
Gharbi 18 (7.5%) 22 (23.7%) 9 (27.3%) 1 (11.1%) 1 (50%) 3 (6.8%)
Other 2 (0.8%) 2 (2.2%) – – – –
Total 240 93 33 9 2 44
Reporting of albendazole usage and follow-up in publications between January 2010 and April 2014
Treatment
N
papers
N patients
(hepatic cysts)
Peri-operative
medical
treatment
Type of albendazole administration
(for publications reporting albendazole
treatment) Follow-up
Y N
Not
stated Continuous Discontinuous
Not
stated
Reported
(months)
Not
stated
Medical treatment
only
10 >29 (>29) – – – 2 8 0 2 (0–16)d 8
Percutaneous
treatment
13 192 (>192) 10a 0 3 6 (1-month therapy) 0 7 10 (3–50) 3
Surgery 72 >10008 (>10008) 53 5b 14 11 6 36 37 (0–120)d 35
Other 2e 2 (>2) 1 1c 0 – – 1 1 (0) 1
Total 96f >10231 (>10231) 64 6 17 17 14 44 50 47
WHO-IWGE, WHO Informal Working Group on Echinococcosis.
aOne publication reported the use of mebendazole.
bIn one case, albendazole was not given because the cyst was classified as a type V calcified cyst; in one case, albendazole was considered too expensive.
cThe patient refused any therapy.
d‘Zero’ follow-up length refers to death or expatriation of patient immediately after treatment.
eOne patient refused therapy; one patient received therapy only for an extrahepatic cyst.
fThe total of publications does not match the sum of the columns because some papers contain data of patients treated in different ways.
Clinical management of cystic echinococcosis Tamarozzi et al.evolution of this infection. Moreover, in the vast
majority of cases, active hepatic infection is an
asymptomatic disease with a spontaneous benign
evolution [22–25], which poses the question
whether treatment is always absolutely required.
So far, no clinical trial has compared all the different
management modalities, and the optimal length ofCopyright © Lippincott Williams & Wilkins. Unau
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0951-7375  2014 Wolters Kluwer Health | Lippincott Williams & Wilkalbendazole treatment is still undefined. This is
mostly because of the chronicity of the disease,
which requires years long follow-up to appropriately
ascertain relapse rates, and to the relative low preva-
lence of diagnosed infection even in endemic areas,
which makes very difficult the design and imple-
mentation of prospective clinical trials. However,thorized reproduction of this article is prohibited.
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CTropical and travel-associated diseasesthe accumulated knowledge based on single-centre
experiences and on the few clinical trials compar-
ing at least some of these treatment modalities
[22,26–28] supports a stage-specific approach to
hepatic cystic echinococcosis [10
&&
,11]. The WHO-
IWGE expert consensus for the diagnosis and treat-
ment of echinococcosis in humans, issued in 2010,
indicated several stage-specific options for the man-
agementofhepatic cystic echinococcosis, although it
also acknowledged that the choice of treatment for
individualpatientsdependsonanumberofvariables,
including not only cyst stage but also other charac-
teristics of the cyst, the patient, and the centre where
the patient is visited [10
&&
]. Additional important
advancements introduced with this document con-
cern the agreement on the use of benzimidazoles.
These should be used as a peri-operative adjuvant
to prevent iatrogenic seeding leading to local or
systemic/extrahepatic secondary echinococcosis.
Furthermore, when used as the only treatment, they
should be administered continuously, without the
2-week interruption between monthly cycles recom-
mended previously. Moreover, the need for a long-
term follow-up of cystic echinococcosis patients was
also stated, although a definite length in years could
not be provided.
Our literature search of scientific papers pub-
lished after January 2010 retrieved 455 results, and,
of these, 96 (69 case reports, 19 cohort/case–control
studies, eight case series) were eligible according to
inclusion criteria. Of the 13 publications describing
percutaneous treatment for hepatic cystic echino-
coccosis, nine indicated the use of peri-operative
albendazole for 1 month after the procedure, one
used mebendazole, but the length of therapy was
not reported, and three did not report any use of
adjuvant medical treatment. Of the 72 papers
describing surgery, 14 did not report any use of
prophylaxis, whereas in five cases, it was stated that
albendazole was not given (in one case because the
cyst was a type V cyst; in one case because of the cost
of albendazole; and in three cases, no explanation
for such a choice was provided). Ten reports used
only medical therapy with benzimidazoles. When
albendazole was given as peri-surgical or as only
therapeutic intervention, 20.6% reported a continu-
ous administration, 22.2% reported a discontinuous
administration, and 57.1% did not mention the
administration modality. Follow-up was described
in half of publications, with a range of 0–120
months. Results are summarized in Table 1.LIMITATIONS
The limitations of this study comprise the inclusion
of works: first, indexed in MEDLINE database only;opyright © Lippincott Williams & Wilkins. Unautho
430 www.co-infectiousdiseases.comsecond, accessible in English, French, Spanish,
Italian, and German; third, without a quality assess-
ment step; and fourth, the restriction to liver echi-
nococcosis. Concerning this last point, however, the
focus on hepatic cystic echinococcosis is justified
by the fact that both WHO-IWGE classification and
Expert Consensus documents mainly refer to this
location. It is therefore likely that the inclusion of
publications on extra-hepatic cystic echinococcosis
might have brought different results. It could be also
argued that the inclusion of case reports may be a
source of bias because case reports by definition
concern ‘unusual or rare features’ as well as ‘un-
expected events’. Therefore, it may be more likely
that only cases from centres with little experience
withhepatic cystic echinococcosis, or thedescription
of only peculiar aspects of hepatic cystic echinococ-
cosis, rather than the ‘routine’ experience of refer-
ence centres, would be published in this format. As
a consequence of these considerations and of the
exclusion of scientific literature in other languages,
it is possible that our results may underestimate the
use ofWHO-IWGE classification and the reception of
the Expert Consensus indications.CONCLUSION
The use of a standardized and internationally
accepted classification of cystic echinococcosis cysts
is not just an academic exercise, given that a corre-
lation exists between cyst morphology and import-
ant aspects of the disease, such as cyst biological
activity, response to treatment, and immunity.
Therefore, diagnostic and therapeutic interventions
need to be evaluated taking into account cyst stages,
and a univocal cyst classification is crucial to allow
comparisons between scientific works. Nonetheless,
we found that the majority of papers published in
the past 10 years, which included data from patients
with hepatic cystic echinococcosis, did not report
any cyst classification. This is particularly striking
when considering serodiagnostic studies, in which
the omission of accounting for cyst stage (occurring
in 55.9% of publications of this type) may lead to
very weak conclusions on tests performances. The
majority of publications included in our reviewwere
case studies. The absence of reporting of cyst classi-
fication was somehow expected in this type of pub-
lication, especially in surgical case reports. However,
we also found a rather low acceptance of indications
on the use of albendazole, as advocated in theWHO-
IWGE expert consensus on diagnosis and treatment
of echinococcosis in 2010, and lack of reporting on
follow-up.
In conclusion, this literature survey shows that
three crucial updates introduced in internationalrized reproduction of this article is prohibited.
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Clinical management of cystic echinococcosis Tamarozzi et al.documents concerning the clinical management of
cystic echinococcosis are still ignored by many. A
joint effort is needed from the scientific community,
including not only scientists but also journal
reviewers, to encourage their use and implementa-
tion. In addition, prospective trials are strongly
needed to clarify themost suitable and cost-effective
approach for every cyst stage, an approach so far
evaluated only in the light of expert opinion and
retrospective data from case series.
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